Skip to main content
OpenTrials

Clinical trial condition

Recurrent Ovarian Carcinoma

Explore clinical trials studying Recurrent Ovarian Carcinoma. Study availability and eligibility vary by location and protocol.

111 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Ovarian Carcinoma trial results

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01489371

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of New Mexico Cancer Center Albuquerque, New Mexico, United States
View Trial Details
Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126

Conditions
Adenocarcinoma, Adnexal Diseases, Adult Hepatocellular Carcinoma, +76 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
View all 61 locations
View Trial Details
Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00939809

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +31 more
Locations
  • Georgia Regents University Medical Center Augusta, Georgia, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Nebraska Methodist Hospital Omaha, Nebraska, United States
  • Stony Brook University Medical Center Stony Brook, New York, United States
View all 16 locations
View Trial Details
Completed

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

NCT00301756

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +22 more
Locations
  • Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada
  • Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario, Canada
  • University Health Network Princess Margaret Cancer Center P2C Toronto, Ontario, Canada
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736

Conditions
Adnexal Diseases, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, +48 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View Trial Details
Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00499252

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Colorado Gynecologic Oncology Group Aurora, Colorado, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Beebe Medical Center Lewes, Delaware, United States
  • Rush University Medical Center Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01118052

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
View Trial Details
Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

NCT01145430

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +30 more
Locations
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Mount Sinai Hospital New York, United States
  • Columbia University/Herbert Irving Cancer Center New York, United States
  • Weill Medical College of Cornell University New York, United States
View Trial Details

Related conditions